What is Intensity Therapeutics Inc Annual Net Profit?

Intensity Therapeutics Inc Annual Net Profit fell 54.37% in the last year to $16.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.

What is Intensity Therapeutics Inc Price to Earning Ratio?

Intensity Therapeutics Inc Price to Earning Ratio is -1.8, which is negative.

What is Intensity Therapeutics Inc Stock Price?

Intensity Therapeutics Inc Stock Price fell 58.58% and underperformed its sector by 57.86% in the past year.

What is Intensity Therapeutics Inc Quarterly Net profit?

Intensity Therapeutics Inc Quarterly Net profit fell 0.28% YoY to $3.18 M. Its sector's average net profit growth YoY for the quarter was -47.42%.

What is Intensity Therapeutics Inc Debt to Equity Ratio?

Intensity Therapeutics Inc Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Intensity Therapeutics Inc Return on Equity(ROE)?

Intensity Therapeutics Inc Return on Equity(ROE) for the last financial year was -202.34%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Intensity Therapeutics Inc Mutual Fund Holding?

Intensity Therapeutics Inc Mutual Fund Holding increased by 0.13% in the last quarter to 3.33.

What is Intensity Therapeutics Inc Institutional Holding?

Intensity Therapeutics Inc Institutional Holding remained the same in the last quarter at 11.58%.

How is the Intensity Therapeutics Inc today?

The Intensity Therapeutics Inc today is trading in the down by -1.53% at 1.93.

How has Intensity Therapeutics Inc performed historically?

The Intensity Therapeutics Inc is currently trading down -1.53% on an intraday basis in the past week the index fell -1.03%. The index has been up 3.76% in the past quarter and fell -58.58% in the past year. You can view this in the overview section.

Intensity Therapeutics Inc XNAS: INTS

Intensity Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Intensity Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Intensity Therapeutics Inc
Rating: 0.65733325
Author: Trendlyne DVM scores

Download real time

1.93 -0.03 (-1.53%)

63.45% Fall from 52W High

27,042 XNAS Volume

XNAS 04 Apr, 2025 5:30 PM (EDT)

Intensity Therapeutics Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	29.3
PE TTM Negative PE TTM Unavailable in chosen country	-1.8
Price to Book High in industry Unavailable in chosen country	10
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	11.6
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-0.3
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-54.4
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	6.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-202.3
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-147.4

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

1.8 / 100

Technically Bearish

24.5 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Intensity Therapeutics Inc Stock Price Analysis

Day Price Range -1.5% 1 Day return Unavailable in chosen country	1.9 (LTP) 1.82 LowHigh
Week Price Range -1.0% 1 Week return Unavailable in chosen country	1.9 (LTP) 1.82.1 LowHigh
Month Price Range -12.7% 1 Month return Unavailable in chosen country	1.9 (LTP) 1.82.5 LowHigh
52 Week Price Range -58.6% 1 Year return Unavailable in chosen country	1.9 (LTP) 1.55.3 LowHigh

View full Share Price History

Intensity Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Intensity Therapeutics Inc Stock Analysis

Intensity Therapeutics Inc stock analysis with key metrics, changes, and trends.

Intensity Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$16.27 M	54.37%	negative	Annual Net Profit fell 54.37% in the last year to $16.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.
Price to Earning Ratio	-1.8	-	negative	Price to Earning Ratio is -1.8, which is negative.
Stock Price	$1.93	-58.58%	negative	Stock Price fell 58.58% and underperformed its sector by 57.86% in the past year.
Quarterly Net profit	$3.18 M	0.28%	negative	Quarterly Net profit fell 0.28% YoY to $3.18 M. Its sector's average net profit growth YoY for the quarter was -47.42%.
Debt to Equity Ratio	0.05	-	positive	Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-202.34 %	-202.34%	negative	Return on Equity(ROE) for the last financial year was -202.34%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	3.33 %	0.13%	positive	Mutual Fund Holding increased by 0.13% in the last quarter to 3.33.
Institutional Holding	11.58 %	0%	neutral	Institutional Holding remained the same in the last quarter at 11.58%.

VIEW LESS

Loading data..

Intensity Therapeutics Inc - Company Profile

What does Intensity Therapeutics Inc do?

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

2024

Gross Remuneration

Year

Intensity Therapeutics Inc Live Share Price Today, Share Analysis and Chart

63.45% Fall from 52W High

Intensity Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Intensity Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Intensity Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Intensity Therapeutics Inc Stock Analysis

Intensity Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 54.37% in the last year to $16.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.

Price to Earning Ratio is -1.8, which is negative.

Stock Price fell 58.58% and underperformed its sector by 57.86% in the past year.

Quarterly Net profit fell 0.28% YoY to $3.18 M. Its sector's average net profit growth YoY for the quarter was -47.42%.

Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -202.34%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.13% in the last quarter to 3.33.

Institutional Holding remained the same in the last quarter at 11.58%.

Intensity Therapeutics Inc - Company Profile

What does Intensity Therapeutics Inc do?

Intensity Therapeutics Inc Management structure

Mr. Lewis H. Bender

President, Chief Executive Officer and Chairman of the Board

Mr. Joseph Talamo

Chief Financial Officer

Mr. John Wesolowski

Principal Accounting Officer and Controller

Mr. James M. Ahlers

Executive Vice President, Corporate Finance

Intensity Therapeutics Inc Board of directors

Dr. Mark A. Goldberg, M.D.

Independent Director

Dr. Emer Leahy, PhD

Independent Director

Mr. Daniel J. Donovan

Independent Director

Mr. Thomas I.H. Dubin

Director

Mr. Lewis H. Bender

President, Chief Executive Officer and Chairman of

Intensity Therapeutics Inc FAQ

How is Intensity Therapeutics Inc today?

Intensity Therapeutics Inc today is trading in the red, and is down by -1.53% at 1.93.

How has Intensity Therapeutics Inc performed historically?

Intensity Therapeutics Inc is currently trading down -1.53% on an intraday basis. In the past week the stock fell -1.03%. stock has been up 3.76% in the past quarter and fell -58.58% in the past year. You can view this in the overview section.